Analysis Article • Aug 16
Have your own idea? Try our Stock Screener
French (CAC) Biotech Industry Analysis
UpdatedAug 20, 2026
DataAggregated Company Financials
Companies22
- 7D-2.9%
- 3M-1.5%
- 1Y45.6%
- YTD-11.2%
Over the last 7 days, the Biotech industry has dropped 3.5%, driven by a pullback from ABIVAX Société Anonyme of 5.5%. On the other hand Nanobiotix is actually up 10%. This takes the industry's 12 month performance to a gain of 44%. Looking forward, earnings are forecast to grow by 60% annually.
Industry Valuation and Performance
Has the French Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 20 Aug 2026 | €11.8b | €482.2m | -€900,752,325.70 | 16.5x | -13.1x | 24.5x |
| Sat, 18 Jul 2026 | €12.9b | €506.8m | -€887,388,264.29 | 19.4x | -14.5x | 25.4x |
| Mon, 15 Jun 2026 | €9.4b | €495.2m | -€860,613,195.80 | 18.6x | -10.9x | 18.9x |
| Wed, 13 May 2026 | €11.3b | €518.0m | -€834,999,411.84 | 16.2x | -13.5x | 21.8x |
| Fri, 10 Apr 2026 | €11.1b | €502.1m | -€819,269,161.82 | 13.5x | -13.6x | 22.1x |
| Sun, 08 Mar 2026 | €10.8b | €560.8m | -€765,563,518.53 | 13x | -14.1x | 19.2x |
| Tue, 03 Feb 2026 | €10.6b | €559.7m | -€763,436,394.32 | 14.3x | -13.9x | 19x |
| Thu, 01 Jan 2026 | €12.1b | €641.5m | -€693,945,582.75 | 9.8x | -17.5x | 18.9x |
| Sat, 29 Nov 2025 | €2.6b | €637.1m | -€431,361,348.64 | 10.6x | -6x | 4.1x |
| Mon, 27 Oct 2025 | €2.5b | €637.2m | -€407,294,787.85 | 10.1x | -6.1x | 3.9x |
| Wed, 24 Sep 2025 | €2.3b | €635.9m | -€451,722,432.41 | 12.9x | -5.2x | 3.7x |
| Fri, 22 Aug 2025 | €2.6b | €674.3m | -€446,545,663.08 | 15.4x | -5.8x | 3.9x |
| Sun, 20 Jul 2025 | €2.0b | €656.2m | -€453,401,230.40 | 15.7x | -4.4x | 3x |
| Tue, 17 Jun 2025 | €2.0b | €666.9m | -€495,948,575.22 | 17.5x | -4.1x | 3x |
| Thu, 15 May 2025 | €2.5b | €671.7m | -€678,883,056.33 | 39.4x | -3.6x | 3.7x |
| Sat, 12 Apr 2025 | €2.1b | €650.7m | -€549,092,612.16 | 14.2x | -3.9x | 3.3x |
| Mon, 10 Mar 2025 | €2.5b | €651.9m | -€521,155,581.40 | 16.6x | -4.7x | 3.8x |
| Wed, 05 Feb 2025 | €2.3b | €650.2m | -€527,164,521.22 | 16.7x | -4.4x | 3.6x |
| Fri, 03 Jan 2025 | €2.4b | €650.9m | -€529,496,316.44 | 18.2x | -4.6x | 3.7x |
| Sun, 01 Dec 2024 | €2.4b | €654.0m | -€547,103,426.84 | 18.5x | -4.4x | 3.7x |
| Tue, 29 Oct 2024 | €2.8b | €641.3m | -€519,366,537.20 | 18.7x | -5.4x | 4.4x |
| Thu, 26 Sep 2024 | €3.0b | €545.5m | -€591,076,284.04 | 27.7x | -5x | 5.4x |
| Sat, 24 Aug 2024 | €3.1b | €520.1m | -€578,507,082.20 | 37.5x | -5.4x | 6x |
| Mon, 22 Jul 2024 | €2.9b | €511.7m | -€566,393,417.73 | 28.9x | -5.1x | 5.7x |
| Wed, 19 Jun 2024 | €3.0b | €514.3m | -€569,042,890.41 | 26.7x | -5.3x | 5.8x |
| Fri, 17 May 2024 | €3.3b | €502.3m | -€592,426,100.94 | 27.9x | -5.6x | 6.6x |
| Sun, 14 Apr 2024 | €3.3b | €515.7m | -€629,475,775.73 | 28.4x | -5.2x | 6.3x |
| Tue, 12 Mar 2024 | €3.1b | €567.7m | -€646,706,019.23 | 21.4x | -4.8x | 5.5x |
| Thu, 08 Feb 2024 | €3.0b | €558.9m | -€675,004,465.79 | 21.7x | -4.4x | 5.4x |
| Sat, 06 Jan 2024 | €3.2b | €594.2m | -€683,028,253.00 | 23.1x | -4.7x | 5.4x |
| Mon, 04 Dec 2023 | €3.2b | €594.5m | -€684,435,706.00 | 21.8x | -4.6x | 5.3x |
| Wed, 01 Nov 2023 | €3.1b | €803.4m | -€567,060,758.00 | 21.4x | -5.5x | 3.9x |
| Fri, 29 Sep 2023 | €3.5b | €861.6m | -€629,774,671.00 | 14.4x | -5.6x | 4.1x |
| Sun, 27 Aug 2023 | €3.7b | €818.2m | -€727,289,207.00 | 24.1x | -5.1x | 4.5x |
Price to Earnings Ratio
-5.1x
Current Industry PE
- Investors are optimistic on the French Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 8.3x is lower than the industry's current PS ratio of 24.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 16% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the French Healthcare industry?
| FR Market | -1.80% | |
| Healthcare | 1.73% | |
| Biotech | -2.94% | |
| Biotech | -2.94% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NANO Nanobiotix | €37.40 | 12.7% +€214.0m | 351.1% | PS58.2x | |
| VLA Valneva | €2.93 | 19.2% +€89.3m | -40.6% | PS3.9x | |
| GNFT Genfit | €14.10 | 5.5% +€37.0m | 277.2% | PS10x | |
| TNG Transgene | €0.84 | 16.4% +€32.3m | -19.0% | PS31.8x | |
| DBV DBV Technologies | €2.49 | 4.5% +€32.0m | 43.2% | PS171.4x |
